In a recent article for Pharmacy Times, RxBenefits Chief Pharmacy Officer Mark Campbell, PharmD, explores the challenges that have prevented biosimilars from delivering on their cost-saving promise.
Campbell highlights how – despite the high expectations for biosimilars to drive down the price of expensive biologics like Humira – market dynamics, formulary challenges, and high introductory pricing have limited adoption and the competition necessary to lower prices.
Key Highlights:
- The complex market dynamics preventing biosimilar uptake
The role of PBM formularies in maintaining high costs
Why biosimilars have not generated the expected savings
What needs to change for biosimilars to fulfill their potential
